Trial Profile
A Phase 1 / 2, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jun 2022
Price :
$35
*
At a glance
- Drugs ONCT 216 (Primary) ; Vincristine (Primary)
- Indications Ewing's sarcoma
- Focus Adverse reactions; First in man
- Sponsors Oncternal Therapeutics, Inc.; Tokalas, Inc.
- 21 Jun 2022 Status changed from active, no longer recruiting to discontinued.
- 19 Apr 2022 Status changed to active, no longer recruiting.
- 13 Apr 2022 According to Oncternal Therapeutics media release, status changed from recruiting to discontinued as the company discontinued enrollment of this Phase 1/2 trial of ONCT-216 in Ewing sarcoma to reallocate resources to our zilovertamab global registrational Phase 3 study ZILO-301, which is expected to be initiated in Q3 2022